CDCP1 and cancer: cancer and PDAC (88.6%) tumors analyzed in this study exhibited CDCP1 immunohistochemical signal well above levels seen by us in 34 normal tissues, suggesting that these patients would most likely benefit from a CDCP1-targeted therapy.